• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print

Corporate Spotlight

Harvest of the first crops to be carried out in May, facility scheduled to be at full capacity by end-June. Cannabis from the facility will be used to service Canada’s large and growing recreational and medicinal marketplace.
View the full Corporate Spotlight arrow Created with Sketch.

Creso Pharma Nova Scotia Facility Tour

CPH TO LAUNCH NEW HEMP PLANT PRODUCT

arrow-down-2 Created with Sketch.


CRESO TO LAUNCH A NEW HEMP PLANT PRODUCT FOR EQUINES AND LARGE ANIMALS

ASX Announcement 11th February 2020


 Highlights 

  • • Creso Pharma has successfully developed anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals 
  • • anibidiol®EQUI is a natural plant product aimed at reducing stress and pain and supporting fast mobility recovery 
  • • The product was developed with Switzerland-based CapService over the last 12 months 


 Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to announce that it plans to launch a new hemp derived animal health product targeted at equines and large animals in the second half of 2020. 


Developed over the past 12 months, anibidiol®EQUI is a flavoured micromilled hemp plant product for large animals, and in particular horses. 


The complementary feed anibidiol®EQUI is based on natural hemp plant components and provides the entourage effect in which the various hemp components work together to strengthen the key benefits, aiming to reduce stress and pain and support fast mobility recovery. 


The product contains natural hemp compounds which are reconigised as traditional feed components already approved for use in consumer products. This represents an additional pathway to market for the Company’s hemp-based complementary feed products without the need for regulatory approval. 


anibidiol®EQUI will be mainly commercialised in LATAM, ASIAPAC and selected European countries, thus increasing the Company’s global commercial foot print.


anibidiol®EQUI is Swiss made, produced out of Swiss Good Agricultural Practice (GAP) compliant industrial hemp.


Dr. Miri Halperin Wernli, Co-Founder and CEO said: “Creso Pharma is excited to add another innovative product to our growing portfolio. anibidiol®EQUI was developed to address the equines and large animals’ needs for a natural plant based complementary feed product to support the management of stress and pain and to enhance well-being. We are pleased to have this product ready for launch later this year.”


CLICK HERE TO VIEW THE FULL ANNOUNCEMENT



Authority and Contact Details 

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited. 

For further information, please contact: 


Investor Enquiries Media Enquiries 

EverBlu Capital Julia Maguire | The Capital Network 

E: [email protected] E: [email protected] 

P: +61 2 8249 0000 P: +61 419 815 386

2.5 MILLION CANNAQUIX® SALES GLOBALLY

arrow-down-2 Created with Sketch.

CRESO PHARMA EXCEEDS MILESTONE OF 2.5 MILLION CANNAQUIX® LOZENGES SOLD GLOBALLY

ASX Announcement 28 January 2020



 Highlights 

  • Creso Pharma’s flagship product line cannaQIX® recently surpassed the significant milestone of 2.5 million lozenges sold, globally, which represents over 100,000 packs sold. 
  • Launched in April 2018, cannaQIX® helps users managing stress and pain as well as improving sleep 
  • Creso Pharma produces and markets cannaQIX® in collaboration with several partners in Europe and Oceania 



 Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to announce that its flagship cannaQIX® line exceeded the significant milestone of 2.5 million lozenges sold, globally, which represents over 100,000 packs sold since its launch in April 2018. Revenue from the sale of cannaQIX® lozenges in 2019 exceeded AUD $1 million (unaudited). 

The cannaQIX® hemp oil derived food supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand. 


Creso Pharma developed cannaQIX® 10 to help manage stress and cannaQIX® 25 and 50 to help manage chronic pain. The initial target markets for these products were Switzerland, UK, Australia, New Zealand and Brazil. 


The Company produces the cannaQIX® range of products in Switzerland and is commercialising them in collaboration with several partners in Europe, Oceania and Latin America. 


The products are being distributed through pharmacies and drug stores in Europe as well as through doctors and clinics in Oceania and Latin America. 


Dr. Miri Halperin Wernli, Co-Founder and CEO said: “We are proud that cannaQIX® has reached this milestone. The cannaQIX® line is Creso Pharma’s hemp oil/vitamins & minerals based food supplement, oral cosmetic and medical cannabis, which has been developed with a unique proprietary buccal delivery system.

The products help manage stress and pain, and support better sleep. We are looking forward to upcoming launches together with our new partners in additional countries and continents such as South Africa and Latin America in 2020.” 


The products available in each country are shown below:


Jorge Wernli, Commercial Director said: “Creso Pharma’s cannaQIX® hemp oil-derived products are unique, all Swiss-made, and produced in GMP facilities complying with local regulatory requirements. Creso Pharma has developed an attractive product portfolio responding to customer needs and complying with regulations. With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialised animal and human health products.”


Authority and Contact Details 

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited. 

For further information, please contact: 

Investor Enquiries Media Enquiries 

EverBlu Capital Julia Maguire | The Capital Network 

E: [email protected] E: [email protected] 

P: +61 2 8249 0000 P: +61 419 815 386



CLICK HERE TO VIEW THE FULL ANNOUNCEMENT

CPH EXCEEDS MILESTONE OF 3M EU SALES

arrow-down-2 Created with Sketch.

Creso exceeds the milestone of 3 million anibidiol® doses sold in Europe

ASX Announcement 21 January 2020


Highlights

  • In a milestone achievement, Creso Pharma has sold over three million anibidiol® portion sachets since the product was launched in late 2017. This volume is estimated to have benefitted over 100,000 dogs.

  • Creso Pharma produces and markets anibidiol® in collaboration with Virbac S.A. (EPA:VIRP) in more than 10 countries.

  • In addition, together with Virbac Switzerland, Creso Pharma has just launched the new product “anibidiol Oil 500” as a lifecycle management enhancement for the anibidiol® range.

  • Two additional hemp-derived products aimed at improving the wellbeing of pets and pet owners will be launched by Creso Pharma in 2020.


Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to announce that over 100,000 dogs are estimated to have benefited from the Company’s anibidiol® range of hemp oil complementary feed products.


This milestone corresponds to over 3 million portion sachets of anibidiol® granules used as complementary feed to help mitigate stress and improve wellbeing in dogs.


Creso Pharma developed anibidiol® and patented its granulated delivery system. It is produced in Switzerland and is commercialised in collaboration with Virbac S.A. (EPA:VIRP) in more than 10 countries in Europe. Its global sales grew approximately 700% in 2019.


anibidiol® Regular and anibidiol® Plus are commercialised for small, medium-sized and large pets to support the reduction of stress and aid in the functioning of the animals’ nervous systems. Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed.


 page2image2004359456 page2image2004359760

Image 1: anibidiol® 2.5 and anibidiol® 8


page2image2004644864
page2image2004644496

Images 3 and 4: anibidiol® regular


Creso Pharma has successfully developed 3 additional hemp-derived products to improve the wellbeing of pets, which are slated for launch during 2020.


Together with Virbac Switzerland, the Company recently launched its new anibidiol® Oil 500 product as a lifecycle management enhancement for the anibidiol® range, responding to strong demand from veterinaries and pet owners.

Initially the product will be marketed in Switzerland, with other national markets being added throughout 2020.


Click here to view the full announcement








ENTER THE AFRICAN CONTINENT

arrow-down-2 Created with Sketch.

Creso Pharma and Pharma Dynamics enter the African continent with the cannaQIX® products range 

ASX Announcement 9 December 2019 


Investment Highlights 

  • Creso Pharma and Pharma Dynamics progress with the preparation of the cannaQIX® product range for 9 African countries to be launched in Q1 2020 
  • Customers in South Africa and region will gain access to an affordable, high-quality, broad-spectrum hemp oil based GMP lozenge nutraceuticalproduct 
  • First production orders for cannaQIX® regular are in process 
  • Pharma Dynamics is a wholly-owned subsidiary of Lupin Limited (NSE:LUPIN), among the top eight leading global generic pharmaceutical companies 
  • The global market penetration of cannaQIX® continues to expandrapidly


CresoPharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘theCompany’) is pleased to announce that the launch preparations of the cannaQIX® range with leading South African pharmaceutical company, Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN) in the first quarter 2020 is on schedule.


Creso Pharma partners with Pharma Dynamics, who has the sole distribution rights of Creso Pharma’s broad-spectrum hemp oil nutraceuticals cannaQIX® product range across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.


In conjunction with execution of the Commercial Agreement, Pharma Dynamics has also made two initial orders for cannaQIX® regular with an approximate value of A$300,000. It is expected that the product will be available at leading South African retail pharmacies in the first quarter 2020.


CannaQIX®’s global market penetration has increased significantly this year. In the June quarter, cannaQIX® became available in major retailers like Holland & Barrett and Boots in the UK, and Creso Pharma received approval to import the product into Brazil and Australia [ASX Announcement: July 24 2019]. 


More recently, Creso announced that it has entered an exclusive distribution agreement with JC Logistics Ltd t/a Medleaf Therapeutics for the exclusive distribution of cannaQIX® in New Zealand [ASX Announcement: August 6 and 8 2019]. Creso also announced the arrival of its first shipment of cannaQIX®50 in Australia, to be sold under the brand name ‘LozaCan’ through its exclusive Australian distributor, Burleigh Heads Cannabis [ASX Announcement: 5 December 2019].


cannaQIX® 10 Regular 

The cannaQIX® range of products are cannabidiol (CBD) hemp oil-based nutraceuticals using Creso Pharma’s proprietary innovative delivery technology. They contain broad spectrum organic hemp oil extract with CBD aiming to reduce stress and to support mental and nervous functions


cannaQIX® regular comes in packs of 24 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth. This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver. By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. The products are sugar-free and contain no tetrahydrocannabinol (THC).


The standardized, user-friendly strength and formulation allows precise dosage control and the lozenges have a more palatable taste compared to oils.


The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a “Swiss Made” label. 


Pharma Dynamics CEO, Erik Roos said: “In line with our ethos of increasing access to affordable, quality medication, we have identified Creso Pharma as our partner of choice. Creso Pharma is globally recognised as a leader in the production of cannabis products with distribution agreements already in place in various countries in Europe and AsiaPac. We are looking forward to the launch of the cannaQIX® range in first African countries.


Dr Miri Halperin Wernli, Creso Pharma’s CEO and Co-Founder said: “ We are very excited to work together with our preferred partner Pharma Dynamics for the launch of the cannaQIX® product range into the first key countries in Africa. We are delighted to offer to the customer a top quality product with a top quality partner at an affordable price.”


Click here to view the full announcement

ARRIVAL OF FIRST SHIPMENT

arrow-down-2 Created with Sketch.

Creso and Burleigh Heads Cannabis announce arrival of first shipment of cannaQIX® 50 in Australia 

ASX Announcement 5 December 2019 


Highlights 

  • Creso Pharma confirms arrival of the first shipment of its innovative therapeutic product cannaQIX® 50 in Australia 
  • cannaQIX® 50 is now being sold in Australia as a medicinal cannabis product under the brand name ‘LozaCan’ via Burleighs Heads Cannabis’ extensive distribution network 
  • Creso Pharma and Burleigh Heads Cannabis are exploring the introduction of additional therapeutic/medicinal products from Creso Pharma’s pipeline of new products to the Australian market


Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to announce that it has commenced sales of its flagship medicinal cannabis product cannaQIX® 50 to Burleigh Heads Cannabis, one of Australia’s leading medicinal cannabis distribution companies. Burleigh Heads Cannabis has confirmed prescriptions are already taking place and the product is receiving very positive feedback from physicians and patients.


Creso Pharma and Burleigh Heads Cannabis have placed initial focus on introducing cannaQIX® 50, which is now being sold in Australia as a therapeutic product via approved channels as ‘LozaCan’. Furthermore, the two entities are exploring potentially expanding the collaboration to include additional therapeutic/medicinal products from Creso Pharma’s pipeline. 


cannaQIX® 50/LozaCan has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by Creso Pharma’s partner, Switzerland-based food and pharma development company Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a ‘Swiss Made’ label.


The delivery follows the recent signing of an exclusive Distribution Agreement with Burleigh Heads Cannabis and the securing of an import permit for Australia [ASX Announcement: April 30 2019]. The collaboration will enable Creso Pharma to leverage Burleigh Heads Cannabis and CDA’s local regulatory experience and established distribution networks to facilitate patient access to its products in Australia.


Burleigh Heads Cannabis is a subsidiary of CDA Health Pty Ltd (‘CDA’), an established Australian business supporting patient access to medical cannabis products in Australia. Through its affordable CDA-branded products and CDA Clinics, CDA assists doctors and patients navigate the process of applying, prescribing and sourcing medical cannabis legally and provide educational resources and one-to-one service from their consultant doctors through physical and telehealth clinics. CDA has completed over 5000 successful Therapeutic Goods Administration (TGA) patient approvals since launching in October 2018.


About cannaQIX® 50/LozaCan 

cannaQIX® 50 is Creso Pharma’s proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain. Each cannaQIX® 50 lozenge contains 50mg of CBD from full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardized pharma-grade formulation produced in Switzerland.


cannaQIX® 50 comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth. This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver.


By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX® 50 lozenges taste great and are a patientfriendly way to administer precise doses of CBD when compared to oil-based alternatives.


Image 1: LozaCan cannaQIX 50® 


Dr Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said: “We are pleased to announce the first delivery of cannaQIX® 50 in Australia. Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network. This close partnership enables us to fulfil our mission of bringing lifeimproving products to patients in Australia. We’re delighted to announce this progress and look forward to further new product introductions in the near future”. 


Mr Guy Headley, Managing Director for Burleigh Heads Cannabis added: "We are delighted to mark this milestone in our collaboration with Creso Pharma. This collaboration will provide Australian patients and doctors with a quality product option to utilise for patient care. By leveraging our experience with Australian regulations and established distribution networks, we believe that we will be able to deliver an innovative product option to benefit patients across Australia.”


Click here to view the full announcement

(20min delay)
Last
11.5¢
Change
-0.005(4.17%)
Mkt cap ! $24.17M
Open High Low Value Volume
11.5¢ 11.5¢ 11.0¢ $165.1K 1.459M

Buyers (Bids)

No. Vol. Price($)
5 183078 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 245070 7
View Market Depth
Last trade - 13.09pm 20/02/2020 (20 minute delay) ?
(live)
Last
11.0¢
  Change
-0.005 ( 4.35 %)
Open High Low Volume
11.5¢ 11.5¢ 11.0¢ 682763
Last updated 14.22pm 20/02/2020 (live) ?
CPH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.